Clintec, a global CRO, has been awarded the Queen¹s Award for Enterprise 2017 in the category of International Trade for a second time.

The Queen’s Award, the highest accolade that can be granted to any business operating within the U.K., recognizes outstanding corporate achievement.

Clintec was selected from amongst some of the top performing UK businesses for its differentiated geographical capability and impressive growth in the mid-market of the contract research sector.

Clintec launched into the clinical research sector 20 years ago and has organically developed a broad, diverse and cohesive geographical footprint spanning over 50 countries with permanent employees.

Powered by the latest technologies in the industry, Clintec provides flexible access to their global platform for clinical trial execution. This value proposition equips their clients with the ability to conduct the most complex of international clinical development programs without the fixed-cost and oversight burden of utilizing their own resources and technology.

Dr. Rabinder Buttar, founder and CEO of Clintec, said, “We are honored to have received the Queen¹s Award for Enterprise again as we celebrate 20 years of global success in clinical research. The people of Clintec are very excited and energized to grow the business further and continue to deliver excellent clinical research solutions to our clients, several of whom have partnered with us for many years.”

Dr. Buttar added, “The United Kingdom has served as a great base from which we have expanded into over 50 countries and we would like to thank all people in the UK and worldwide who have supported us along our incredible journey.”

Clintec’s extensive global reach throughout Western Europe, Central and Eastern Europe, Middle East and North Africa, Sub-Saharan Africa, Asia Pacific and North America, provides access to both developed and emerging markets, and all to the global clinical and ethical standards required for high-quality drug development.

Clintec specializes in clinical research solutions and functional service provision across phases I-IV in drug development with particular expertise in oncology and rare diseases. The company is developing innovative best-in-class treatments within the immuno-oncology space, to assist patients with various forms of cancer to obtain new and much needed therapies. The company partners with many of the world¹s global pharmaceutical companies, as well as smaller biotechnology companies, to fast-track their product development using innovative and flexible outsourcing solutions underpinned with an entrepreneurial and client-centric approach.

The award will be bestowed upon Clintec by Her Majesty The Queen on the advice of the Prime Minister.